Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | PRCP | P42785 | 2/20 | 1.00 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.53 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.53 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.53 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.53 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742361 | 1.00 | SIGMAR1 (1.00) | SIGMAR1MEN1KMT2APRCPSLC6A9 | |
| Tenocyclidine SCHEMBL7204633 | 0.98 | SIGMAR1 (0.97) | SIGMAR1MEN1KMT2APRCPSLC6A9 | |
| Rolicyclidine SCHEMBL15476513 | 0.91 | SIGMAR1 (0.82) | SIGMAR1MEN1KMT2APRCPSLC6A9 | |
| SCHEMBL7701615 | 0.88 | SIGMAR1 (0.79) | SIGMAR1MEN1KMT2APRCPSLC6A9 | |
| SCHEMBL7695403 | 0.87 | SIGMAR1 (0.77) | SIGMAR1MEN1KMT2APRCPSLC6A9 | |
| SCHEMBL29406833 | 0.85 | SIGMAR1 (0.74) | SIGMAR1MEN1KMT2APRCPSLC6A9 | |
| SCHEMBL7703474 | 0.84 | SIGMAR1 (0.72) | SIGMAR1MEN1KMT2APRCPSLC6A9 | |
| SCHEMBL8867380 | 0.84 | SIGMAR1 (0.72) | SIGMAR1MEN1KMT2APRCPSLC6A9 | |
| SCHEMBL8866891 | 0.84 | SIGMAR1 (0.73) | SIGMAR1MEN1KMT2APRCPSLC6A9 | |
| Tenocyclidine SCHEMBL28321720 | 0.83 | SIGMAR1 (0.68) | SIGMAR1MEN1KMT2APRCPSLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 680 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539337-B2 | Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels | Molokanova, Elena (US) | 2026-02-03 | — | — | US | claimed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| US-20240350433-A1 | TREATMENT COMPOSITIONS AND METHODS | UNIV YALE (US) | 2024-10-24 | — | — | US | claimed |
| WO-2024123935-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | FREEDOM BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| WO-2024074850-A1 | A TREATMENT FOR MENTAL DISORDERS | ReWire Therapeutics Limited (GB) | 2024-04-11 | — | — | WO | claimed |
| US-20240066003-A1 | NEURODEVELOPMENTAL DISORDER THERAPY | ANAVEX LIFE SCIENCES CORP. (US) | 2024-02-29 | — | — | US | claimed |
| WO-2023196234-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-12 | — | — | WO | claimed |
| US-20230310380-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-05 | — | — | US | claimed |
| US-20040242848-A1 | Mouse/human chimeric anti-phencyclidine antibody and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-12-02 | — | — | US | claimed |
| EP-1438020-A2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING PAIN | EpiCept Corporation (US) | 2004-07-21 | — | — | EP | claimed |
| US-20040076648-A1 | Topical compositions and methods for treating pain | EPICEPT CORPORATION | 2004-04-22 | — | — | US | claimed |
| US-20030082214-A1 | Topical compositions and methods for treating pain | DISCOVER GROWTH FUND, LLC (VI) | 2003-05-01 | — | — | US | claimed |
| WO-2003015699-A2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING PAIN | EPICEPT CORPORATION (US) | 2003-02-27 | — | — | WO | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| WO-1998010757-A9 | THE USE OF FUNCTIONAL N-METHYL-D-ASPARTATE ANTAGONISTS TO AMELIORATE OR PREVENT AMINOGLYCOSIDE-INDUCED OTOTOXICITY | — | 1998-07-23 | — | — | WO | claimed |
| WO-1998010757-A2 | THE USE OF FUNCTIONAL N-METHYL-D-ASPARTATE ANTAGONISTS TO AMELIORATE OR PREVENT AMINOGLYCOSIDE-INDUCED OTOTOXICITY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-03-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539337-B2 | Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels | GRIN2B, GRIN2A, GRIN3A | SIGMAR1 123/4885MEN1 3762/4885KMT2A 3507/4885 |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GRIN2A, GRIN1, GRIN3A | SIGMAR1 99/4885MEN1 4388/4885KMT2A 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.